Boudreau, Carolyn M.
Burke, John S. IV
Yousif, Ashraf S.
Sangesland, Maya
Jastrzebski, Sandra
Verschoor, Chris http://orcid.org/0000-0001-6190-2655
Kuchel, George http://orcid.org/0000-0001-8387-7040
Lingwood, Daniel http://orcid.org/0000-0001-5631-9238
Kleanthous, Harry http://orcid.org/0000-0001-7115-235X
De Bruijn, Iris
Landolfi, Victoria
Sridhar, Saranya http://orcid.org/0000-0002-4267-3102
Alter, Galit
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U19AI42790-01, P01AI1650721, U01CA260476 – 01, CIVIC75N93019C00052, T32 AI007245, T32 AI007245)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Article History
Received: 17 February 2023
Accepted: 7 August 2023
First Online: 24 August 2023
Competing interests
: G.A. is a founder and equity holder of Seromyx Systems, a company developing a platform technology that describes the antibody immune response. C.M.B. is an employee and equity holder of Leyden Labs, a company developing pandemic-prevention therapeutics. G.A. is an employee and equity holder in Moderna, a company developing mRNA therapeutics and vaccines. H.K. is an employee and equity holder in SK Biosciences, a vaccine developer. I.D.B., V.L., and S.S. are employees of Sanofi Pasteur, Inc. The remaining authors declare no competing interests.